P29679.A10

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. - 137. (cancelled)

138. (previously presented) A pharmaceutical or cosmetic composition comprising at least one of a pharmaceutically or cosmetically acceptable carrier and a pharmaceutically or cosmetically acceptable adjuvant and at least one active ingredient selected from a compound of formula:

and pharmaceutically acceptable salts thereof.

139. (previously presented) A method of inhibiting an activity of at least one enzyme selected from alanyl aminopeptidases, dipeptidyl peptidase and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 138 in an amount sufficient for inhibiting the activity of the at least one enzyme.

140. (currently amended) A method of preventing or treating at least one condition selected from[[,]] Morbus Crohn, Colitis ulcerosa, rheumatoid arthritis, diabetes type I, autoimmune thyroid gland diseases, Morbus Wegener, systemic Lupus erythematosus visceralis and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale, allergic rhinitis, food allergy, atopic eczema, contact dermatitis, urticaria, angioedema and other allergic diseases; rejection of allogenic or xenogenic transplanted organs, tissues and cells such as, e.g. kidney, heart, liver, pancreas, skin or stem cell transplants; graft-versus-host diseases; skin and mucosa diseases; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts; acute neuronal diseases, in particular ischemia-caused cerebral damages after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Alzheimer's disease, Pick's disease, Progressive Supranuclear Palsy, cortical degeneration, frontotemporal dementia, Parkinson's disease, Huntington's disease, prion-caused diseases and amyotrophic lateral sclerosis; and chronic obstructive pulmonal diseases disease (COPD); prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions in a subject in need thereof, wherein the method comprises administering to the subject the composition of claim 138 in an amount sufficient for preventing or treating the at least one condition.

141. (currently amended) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, reperfusion syndrome and stent restenosis in a subject in need thereof, wherein the method comprises administering to the subject the

P29679.A10

composition of claim 138 in an amount sufficient for preventing or treating the at least one condition.

142. (previously presented) The method of claim 141, wherein the method comprises administering the composition by using a stent which is coated with the at least one of a composition and an active ingredient thereof.

143. (currently amended) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism the composition of claim 138 in an amount sufficient for preventing or treating the inflammation reaction.

144. (previously presented) The method of claim 143, wherein the method comprises administering the composition at least one of as a coating or layer on the medical device and incorporated in the medical device.

145. (previously presented) The method of claim 143, wherein the method comprises administering the composition by at least one of a local and a systemic administration successively or concurrently.

146. (new) The method of claim 140, wherein the at least one condition comprises multiple sclerosis.

P29679.A10

- 147. (new) The method of claim 140, wherein the at least one condition comprises Colitis ulcerosa.
- 148. (new) The method of claim 140, wherein the at least one condition comprises allergic asthma bronchiale.
- 149. (new) The method of claim 140, wherein the at least one condition comprises chronic obstructive pulmonal disease (COPD).
- 150. (new) The method of claim 140, wherein the at least one condition comprises an inflammatory disease.
- 151. (new) The method of claim 141, wherein the at least one condition comprises atherosclerosis.
- 152. (new) The method of claim 141, wherein the at least one condition comprises arterial inflammation.